David G. Maloney, MD, PhD, reviews the protocols and infrastructure necessary to deliver chimeric antigen receptor T-cell therapy to patients receiving treatment in the outpatient setting.
David G. Maloney, MD, PhD, of the Fred Hutchinson Cancer Research Center, reviews the protocols and infrastructure necessary to deliver chimeric antigen receptor (CAR) T-cell therapy to patients receiving treatment in the outpatient setting.
He said that this process requires a robust clinical ability by the centers and administration staff. The agent lisocabtagene maraleucel (liso-cel) has allowed certain academic centers to pioneer this approach, due to lower rate of severe grade 3 cytokine release syndrome and a slower onset of symptoms. This has made the agent more attractive for use in patients who can be closely monitored following the administration of their therapy.
It is important that patients have access to an emergency department that is capable of treating the potential complicating events associated with CAR T-cell therapy immediately, even if symptoms come on in the middle of the night. That means, patients must stay within 20 to 30 minutes of the center for the first few weeks. In addition, daily monitoring with visits to the center are necessary following the first administration.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More